BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that the updated BD Alaris™ Infusion System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), which enables both remediation and a return to full commercial operations for the most comprehensive infusion system available in the United States....
Initial clinical study results will inform pivotal clinical trial in U.S. and Europe...
Technology enables inference of subjective outcomes from routinely collected data...
Surgeons in the Division of Thoracic Surgery at JFK University Medical Center first in the State of New Jersey to perform this surgery...
According to the American Cancer Society, about 1 out of every 8 men will be diagnosed with prostate cancer during his lifetime...
Optina Diagnostics' pioneering pivotal REPHRASE study, currently underway, is poised to revolutionize the diagnosis and management of Alzheimer's Disease (AD). This landmark study is focused on validating the novel awAIr™-Cerebral Amyloid Status (CAS) test, an innovative tool intended to provide physicians with definitive information about Alzheimer's pathology, enabling improved management of cognitive impairments....
Patient-Led Global Summit on Science, Policy, and Care Choice Drives Optimism...
OncoBindTM IDE Approved to Study Metastatic Cancer...
hrough this partnership, Strive Health, Prominence Health Plan and Sierra Nevada Specialty Care will bring high-quality care to patients with kidney disease across Nevada...
Leading Global Skincare Brand Reinforces Commitment to Menopausal Skincare by Joining Forces with Innovative Wellness Technology to Empower Women During the Menopause Transition...
